PDCD1 and non-small cell lung carcinoma: This score is predictive of response to pembrolizumab (anti-PD-1 ab), and the lack of IFN-γ-associated gene expression is associated with lack of clinical benefit in ICB treatment of melanoma, NSCLC, and gastric cancers [39].